
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV is experiencing significant developments in its gene therapy pipeline, particularly highlighted by the robust efficacy data from AMT-130, which the management asserts represents a groundbreaking standard within the Huntington's disease community. The ongoing collaborations, particularly with Bristol Myers Squibb, enhance the company's capabilities in addressing cardiovascular diseases, while recent trial expansions for AMT-260 in mesial temporal lobe epilepsy demonstrate a proactive approach to broadening its therapeutic portfolio. Despite increased SG&A expenses, the management's emphasis on AMT-130's favorable risk-benefit profile and the absence of regulatory concerns suggests a sustainable pathway forward, reinforcing a positive long-term outlook for the company's operational and financial performance.
Bears say
uniQure NV faces significant challenges that negatively impact its outlook, primarily due to delays in the Biologics License Application (BLA) submission, which management has withdrawn from its previous guidance. The company's positioning is further weakened by the competitive landscape, as existing and emerging therapies threaten its market share and pricing strategies. Financially, uniQure remains a clinical stage company without any revenue-generating products and has consistently incurred losses, exacerbated by the potential for extended development timelines and increased costs amid ongoing clinical setbacks.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares